BioLife Solutions Beheer
Beheer criteriumcontroles 2/4
De CEO BioLife Solutions is Rod de Greef, benoemd in Oct2023, heeft een ambtstermijn van 1.08 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 6.39M, bestaande uit 3.1% salaris en 96.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.15% van de aandelen van het bedrijf, ter waarde $ 1.74M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3 jaar en 16 jaar.
Belangrijke informatie
Rod de Greef
Algemeen directeur
US$6.4m
Totale compensatie
| Percentage CEO-salaris | 3.1% |
| Dienstverband CEO | 1.1yrs |
| Eigendom CEO | 0.1% |
| Management gemiddelde ambtstermijn | 3yrs |
| Gemiddelde ambtstermijn bestuur | 16yrs |
Recente managementupdates
Recent updates
Is BioLife Solutions (NASDAQ:BLFS) Using Debt Sensibly?
Oct 25
Is There An Opportunity With BioLife Solutions, Inc.'s (NASDAQ:BLFS) 20% Undervaluation?
Sep 14Why BioLife Solutions, Inc. (NASDAQ:BLFS) Could Be Worth Watching
Aug 30Investors Appear Satisfied With BioLife Solutions, Inc.'s (NASDAQ:BLFS) Prospects As Shares Rocket 28%
Aug 14BioLife Solutions (NASDAQ:BLFS) Has Debt But No Earnings; Should You Worry?
Jun 20A Look At The Fair Value Of BioLife Solutions, Inc. (NASDAQ:BLFS)
Jun 05Revenues Not Telling The Story For BioLife Solutions, Inc. (NASDAQ:BLFS) After Shares Rise 25%
May 14Broker Revenue Forecasts For BioLife Solutions, Inc. (NASDAQ:BLFS) Are Surging Higher
May 13Should You Investigate BioLife Solutions, Inc. (NASDAQ:BLFS) At US$19.54?
May 11Does BioLife Solutions (NASDAQ:BLFS) Have A Healthy Balance Sheet?
Mar 12BioLife Solutions, Inc.'s (NASDAQ:BLFS) Intrinsic Value Is Potentially 64% Above Its Share Price
Feb 19BioLife Solutions, Inc.'s (NASDAQ:BLFS) Share Price Matching Investor Opinion
Dec 19Downgrade: Here's How Analysts See BioLife Solutions, Inc. (NASDAQ:BLFS) Performing In The Near Term
Aug 17Is BioLife Solutions (NASDAQ:BLFS) Weighed On By Its Debt Load?
Aug 11Health Check: How Prudently Does BioLife Solutions (NASDAQ:BLFS) Use Debt?
May 06Should You Think About Buying BioLife Solutions, Inc. (NASDAQ:BLFS) Now?
Feb 22Health Check: How Prudently Does BioLife Solutions (NASDAQ:BLFS) Use Debt?
Jan 10Is There An Opportunity With BioLife Solutions, Inc.'s (NASDAQ:BLFS) 20% Undervaluation?
Dec 10BioLife: What The Future Holds
Oct 19BioLife Solutions COO Roderick de Greef to retire
Oct 03BioLife Solutions (NASDAQ:BLFS) Has Debt But No Earnings; Should You Worry?
Sep 27Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$64m |
| Mar 31 2024 | n/a | n/a | -US$62m |
| Dec 31 2023 | US$6m | US$199k | -US$66m |
| Sep 30 2023 | n/a | n/a | -US$93m |
| Jun 30 2023 | n/a | n/a | -US$74m |
| Mar 31 2023 | n/a | n/a | -US$141m |
| Dec 31 2022 | US$2m | US$450k | -US$140m |
| Sep 30 2022 | n/a | n/a | -US$106m |
| Jun 30 2022 | n/a | n/a | -US$96m |
| Mar 31 2022 | n/a | n/a | -US$15m |
| Dec 31 2021 | US$1m | US$412k | -US$9m |
| Sep 30 2021 | n/a | n/a | US$5m |
| Jun 30 2021 | n/a | n/a | US$4m |
| Mar 31 2021 | n/a | n/a | -US$20m |
| Dec 31 2020 | US$3m | US$391k | US$2m |
| Sep 30 2020 | n/a | n/a | US$7m |
| Jun 30 2020 | n/a | n/a | US$16m |
| Mar 31 2020 | n/a | n/a | US$39m |
| Dec 31 2019 | US$1m | US$403k | -US$2m |
| Sep 30 2019 | n/a | n/a | -US$32m |
| Jun 30 2019 | n/a | n/a | -US$39m |
| Mar 31 2019 | n/a | n/a | -US$44m |
| Dec 31 2018 | US$490k | US$350k | -US$25m |
| Sep 30 2018 | n/a | n/a | US$1m |
| Jun 30 2018 | n/a | n/a | -US$146k |
| Mar 31 2018 | n/a | n/a | -US$2m |
| Dec 31 2017 | US$520k | US$300k | -US$3m |
Compensatie versus markt: De totale vergoeding ($USD 6.39M ) Rod } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 3.23M ).
Compensatie versus inkomsten: De vergoeding van Rod is gestegen terwijl het bedrijf verliesgevend is.
CEO
Rod de Greef (64 yo)
1.1yrs
Tenure
US$6,387,586
Compensatie
Mr. Roderick de Greef, also known as Rod, serves as Director of BioLife Solutions, Inc. since January 03, 2023 and serves as its Chief Executive Officer & Chairman since October 20, 2023. He had been Presi...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Chairman | 1.1yrs | US$6.39m | 0.15% $ 1.7m | |
| Chief Financial Officer | 3yrs | US$1.70m | 0.27% $ 3.2m | |
| Chief Quality & Operations Officer | less than a year | US$1.12m | 0.34% $ 4.1m | |
| Chairman of Scientific Advisory Board | 4.9yrs | US$1.35m | 0.69% $ 8.2m | |
| Chief Marketing Officer | 9.8yrs | US$734.45k | 0.23% $ 2.8m | |
| Chief Human Resources Officer | 3.8yrs | geen gegevens | 0.13% $ 1.6m | |
| Chief Revenue Officer | 1.1yrs | geen gegevens | 0.25% $ 3.0m |
3.0yrs
Gemiddelde duur
52yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van BLFS wordt beschouwd als ervaren (gemiddelde ambtstermijn 3 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Chairman | 1.8yrs | US$6.39m | 0.15% $ 1.7m | |
| Chairman of Scientific Advisory Board | no data | US$1.35m | 0.69% $ 8.2m | |
| Member of Scientific Advisory Board | 18.1yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 17.2yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 18.1yrs | geen gegevens | geen gegevens | |
| Member of the Scientific Advisory Board | no data | US$284.00k | geen gegevens | |
| Member of Scientific Advisory Board | 17.2yrs | geen gegevens | geen gegevens | |
| Member of the Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Lead Director | 3.6yrs | US$269.17k | 0.039% $ 471.2k | |
| Independent Director | 3.1yrs | US$250.00k | 0.065% $ 773.6k | |
| Member of Scientific Advisory Board | 16yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 12.8yrs | geen gegevens | geen gegevens |
16.0yrs
Gemiddelde duur
59yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van BLFS zijn ervaren en ervaren (gemiddelde ambtstermijn van 16 jaar).